Skip to main content

Table 2 First order correlations between study characteristics (Pearson), N = 153

From: The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials – A secondary analysis

 

%_T

%_P

DUR.

DIA_E

DIA_F0

DIA_F1

DIA_F4

DIA_G

DIA_ I1

DIA_ I2

PREV

INDEXQR

%_T

1,00

,78***

,29***

,01

-,14

-,33***

,01

-,31***

,14

,37***

,49***

,03

%_P

 

1,00

,41***

,07

-,16*

-,19*

-,11

-,30***

,12

,45***

,59***

,08

DUR.

  

1,00

,26**

-,08

-,18*

-,18*

-,16

,41***

,25**

,40***

,12

DIA_E

   

1,00

-,04

-,11

-,07

-,07

-,04

-,10

,25**

-,15

DIA_F0

    

1,00

-,07

-,05

-,05

-,03

-,07

,05

-,05

DIA_F1

     

1,00

-,13

-,14

-,08

-,19*

-,27**

-,03

DIA_F4

      

1,00

-,09

-,05

-,12

-,22**

-,02

DIA_G

       

1,00

-,06

-,13

-,24**

-,06

DIA_I1

        

1,00

-,08

,01

,05

DIA_I2

         

1,00

,54***

,14

PREV

          

1,00

,11

INDEXQR

           

1,00

  1. *) p < .05 **) p < .01 ***) p < .001
  2. Legend: %_T Percent of patients improved with treatment
  3. %_P Percent of patients improved with placebo
  4. DUR. Duration of study in months
  5. DIA_E: Diabetes, other diseases of secretory glands and metabolism
  6. DIA_F0: Dementia
  7. DIA_F1: Behavioural disorders due to psychotropic substances
  8. DIA_F4: Panic disorders
  9. DIA_G: Epilepsy
  10. DIA_I1: High blood pressure
  11. DIA_I2: Ischemic and other forms of heart disease
  12. PREV. Studies with preventive targets
  13. INDEXQR Quality index